Science-first reviews
of research peptides.

A synthetic version of a naturally occurring peptide that promotes cell migration and differentiation. Extensively studied for its role in tissue repair, particularly in cardiac and skeletal muscle recovery models.

A growth hormone releasing hormone analogue with an extended half-life due to Drug Affinity Complex (DAC) technology. Research shows sustained GH pulse elevation in animal models, with implications for body composition and metabolism studies.

Developed in Russia as an ACTH analogue, Semax is a heptapeptide with well-documented nootropic and neuroprotective effects in animal and limited human research. Shown to increase BDNF expression in the hippocampus in rodent studies.

A tetrapeptide studied for its telomere-lengthening properties and anti-aging potential. Research from the St. Petersburg Institute of Bioregulation has documented life-extension effects in animal models spanning several decades of longitudinal study.

A mitochondrially encoded peptide that regulates metabolic homeostasis by targeting the folate cycle and de novo purine synthesis. Emerging research links it to insulin sensitivity, exercise mimicry, and potential implications in metabolic disease models.

A naturally occurring copper complex with documented roles in wound healing, skin remodeling, and anti-inflammatory signaling. Research shows it upregulates collagen synthesis and activates over 4,000 genes linked to tissue repair and renewal pathways.

A selective growth hormone secretagogue peptide with a clean pulse profile. Unlike other GHRPs, Ipamorelin does not significantly stimulate cortisol or prolactin release, making it one of the most studied selective GH-release agents in preclinical research.

A GLP-1 receptor agonist with the most robust clinical evidence of any peptide in this category. Originally developed for type 2 diabetes, it has become the subject of extensive obesity research due to its effects on appetite regulation, gastric emptying, and energy homeostasis.

The first dual GIP and GLP-1 receptor agonist studied in metabolic disease and obesity models. Clinical trial data has shown superior weight reduction outcomes versus semaglutide alone, representing the next generation of metabolic peptide research.

A hexapeptide that stimulates GH release via ghrelin receptor activation. Research has demonstrated strong GH pulse amplification, appetite stimulation, and hepatoprotective properties in rodent models. A classic in GH secretagogue research.

A modified fragment of human growth hormone (hGH 177-191) specifically engineered to target lipolysis without the anabolic or insulin-desensitizing effects of full-length GH. Australian Phase II trials studied its application in obesity treatment.

A 21-amino-acid mitochondrially encoded peptide identified in the 16S rRNA gene. Research implicates it in Alzheimer's protection, insulin sensitivity modulation, and cellular stress response. Plasma levels decline with age, raising interest in longevity research contexts.

The most advanced metabolic peptide currently in clinical research — Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trial data published in the New England Journal of Medicine showed up to 24% body weight reduction at 48 weeks, outperforming all predecessors. Its glucagon component adds direct fat-burning and energy expenditure effects not seen in dual agonists.

A D-retro-inverso peptide designed to disrupt the FOXO4–p53 protein interaction that keeps senescent cells alive. Published research in Cell (2017) demonstrated selective clearance of senescent cells in mouse models, improving physical fitness, fur density, and renal function. One of the most compelling senolytic compounds in preclinical longevity research.

A mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it stabilizes cardiolipin and improves electron transport chain efficiency. SS-31 has shown strong preclinical results in models of heart failure, ischemia-reperfusion injury, and age-related mitochondrial dysfunction. One of the most clinically advanced mitochondrial peptides, with Phase II human trials completed.

A naturally occurring neuropeptide and potent activator of the HPG (hypothalamic-pituitary-gonadal) axis. Kisspeptin-10 is the bioactive C-terminal fragment of the KISS1 gene product and acts as the primary upstream regulator of GnRH pulsatility. Research covers applications in reproductive endocrinology, LH/FSH pulsatility, testosterone regulation, and libido-related signaling pathways. Has reached human clinical trials for hypogonadotropic hypogonadism.

A synthetic small-molecule quinolinium compound that selectively inhibits the enzyme nicotinamide N-methyltransferase (NNMT). By blocking NNMT, it preserves nicotinamide for NAD+ synthesis and modulates SAM-dependent methylation — resulting in measurable effects on fat cell signaling, energy metabolism, and mitochondrial function in preclinical models. Research interest has grown significantly alongside NAD+ and metabolic longevity research trends.

A synthetic analogue of the human tetrapeptide Tuftsin, Selank has been studied for anxiolytic and nootropic effects without the sedative profile typical of benzodiazepines. Russian clinical research has examined its use in generalized anxiety disorder.